Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Aug;49(2):257-65.

Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles

Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles

A Vincent et al. Clin Exp Immunol. 1982 Aug.

Abstract

We have investigated anti-acetylcholine receptor (AChR) characteristics in three forms of generalized myasthenia gravis, which are distinguishable by their thymic pathology, age of onset, sex incidence and HLA antigen associations, and in restricted ocular myasthenia. Light chain, IgG subclass, avidity for denervated human AChR and reaction with various human and mammalian AChR preparations were examined in 9-12 patients from each group. Characteristics varied between individuals in each group but no significant differences were found in mean values between the three groups with generalized myasthenia. When antibody characteristics in ocular myasthenia were compared with those in generalized disease, however, differences were found particularly in relative reactivity with denervated, normal and ocular human AChR. The nature of the humoral response in ocular myasthenia thus differs from that in generalized myasthenia. The similarity in the humoral response between the three groups of generalized myasthenia suggests, on the other hand, that the distinguishing clinical features may reflect differing susceptibilities to diverse precipitating mechanisms.

PubMed Disclaimer

References

    1. Mt Sinai J Med. 1971 Nov-Dec;38(6):497-537 - PubMed
    1. Vox Sang. 1971 Apr;20(4):289-305 - PubMed
    1. Adv Immunol. 1973;16:1-59 - PubMed
    1. Ann N Y Acad Sci. 1976;274:652-8 - PubMed
    1. Neurology. 1976 Nov;26(11):1054-9 - PubMed

Publication types

LinkOut - more resources